TY - JOUR
T1 - Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes
T2 - A Cross-Sectional Study
AU - Berg, Anna Korsgaard
AU - Nørgaard, Kirsten
AU - Thyssen, Jacob P
AU - Zachariae, Claus
AU - Hommel, Eva
AU - Rytter, Karen
AU - Svensson, Jannet
PY - 2018/7
Y1 - 2018/7
N2 - BACKGROUND: In the future, widespread use of closed-loop infusion (artificial pancreas) systems to treat type 1 diabetes (T1D) may significantly improve glycemic control and enhance treatment flexibility. However, the infusion sets and plasters necessary for these treatments can cause dermatological complications that may hamper the spread of the new technology; few studies have investigated these complications in adults. The aim of this study was to describe the dermatological complications associated with continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in adults.METHODS: A total of 118 adult patients from two different diabetes clinics completed a questionnaire concerning the dermatological complications associated with their CSII and/or CGM treatment, other treatment variables, duration of diabetes, allergies, skin care, and other pathologies.RESULTS: CGM or CSII use was associated with current eczema, scars, and wounds. In total, 34% of CSII users and 35% of CGM users currently had one or more skin lesions due to the use of these devices. We found no significant association with glycated hemoglobin (HbA1c) levels, a history of atopic dermatitis, or other skin pathologies. However, multivariate analysis revealed associations with a history of atopy and CSII-associated dermatological complications.CONCLUSIONS: Dermatological complications were present in one in every three patients and represent a significant challenge to using CSII and CGM to treat adults with T1D. Prospective studies on the causes of these complications will be required to develop preventive strategies and ensure that optimal diabetes treatment approaches that take advantage of the latest technology can be implemented.
AB - BACKGROUND: In the future, widespread use of closed-loop infusion (artificial pancreas) systems to treat type 1 diabetes (T1D) may significantly improve glycemic control and enhance treatment flexibility. However, the infusion sets and plasters necessary for these treatments can cause dermatological complications that may hamper the spread of the new technology; few studies have investigated these complications in adults. The aim of this study was to describe the dermatological complications associated with continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in adults.METHODS: A total of 118 adult patients from two different diabetes clinics completed a questionnaire concerning the dermatological complications associated with their CSII and/or CGM treatment, other treatment variables, duration of diabetes, allergies, skin care, and other pathologies.RESULTS: CGM or CSII use was associated with current eczema, scars, and wounds. In total, 34% of CSII users and 35% of CGM users currently had one or more skin lesions due to the use of these devices. We found no significant association with glycated hemoglobin (HbA1c) levels, a history of atopic dermatitis, or other skin pathologies. However, multivariate analysis revealed associations with a history of atopy and CSII-associated dermatological complications.CONCLUSIONS: Dermatological complications were present in one in every three patients and represent a significant challenge to using CSII and CGM to treat adults with T1D. Prospective studies on the causes of these complications will be required to develop preventive strategies and ensure that optimal diabetes treatment approaches that take advantage of the latest technology can be implemented.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biosensing Techniques
KW - Blood Glucose/analysis
KW - Blood Glucose Self-Monitoring/instrumentation
KW - Cicatrix/etiology
KW - Cross-Sectional Studies
KW - Diabetes Mellitus, Type 1/blood
KW - Eczema/etiology
KW - Female
KW - Glycated Hemoglobin A/analysis
KW - Humans
KW - Hypoglycemic Agents/administration & dosage
KW - Insulin/administration & dosage
KW - Insulin Infusion Systems/adverse effects
KW - Male
KW - Middle Aged
KW - Pancreas, Artificial
KW - Surveys and Questionnaires
KW - Young Adult
U2 - 10.1089/dia.2018.0088
DO - 10.1089/dia.2018.0088
M3 - Journal article
C2 - 29893593
SN - 1520-9156
VL - 20
SP - 475
EP - 482
JO - Diabetes Technology & Therapeutics
JF - Diabetes Technology & Therapeutics
IS - 7
ER -